Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy, presents the collation of chapters written by eminent scientists worldwide. CRISPR-Cas9 is a key technology for targeted genome editing and regulation in a number of organisms including mammalian cells. It is a rapid, simple, and cost-effective solution. CRISPR-Cas system has recently gained much scientific and public attention. This volume covers CRISPR-Cas9 based mammalian genome editing, creating disease models, cancer therapy, neurological, heredity, blood disorders, defective gene correction, stem cells therapy, epigenetic modifications, patents, ethics, biosafety and regulatory issues challenges and opportunities. This book is a key source of information on mammalian genome editing available in a single volume. This book will be useful for beginners in mammalian genome editing and also students, researchers, scientists, policymakers, clinicians and stakeholders interested in genome editing in several areas.
1. Chapter One: An introduction to CRISPR-Cas systems for reprogramming the genome of mammalian cells - p. 1 2. Chapter Two: CRISPR-Cas systems for genome editing of mammalian cells - p. 15 3. Chapter Three: Genome-wide detection and analysis of CRISPR-Cas off-targets - p. 31 4. Chapter Four: CRISPR-based diagnostics for detection of pathogens - p. 45 5. Chapter Five: Creating cell lines for mimicking diseases - p. 65 6. Chapter Six: Modulating Cas9 activity for precision gene editing - p. 99 7. Chapter Seven: CRISPR-Cas9 in cancer therapeutics - p. 129 8. Chapter Eight: CRISPR-Cas9 for treating hereditary diseases - p. 165 9. Chapter Nine: CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals - p. 199 10. Chapter Ten: Recent advances in stem cells and gene editing: Drug discovery and therapeutics - p. 253 11. Chapter Eleven: Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms - p. 271 12. Chapter Twelve: Genome editing in cardiovascular diseases - p. 289 13. Chapter Thirteen: CRISPR/Cas9 in epigenetics studies of health and disease - p. 326 14. Chapter Fourteen: Patents, ethics, biosafety and regulation using CRISPR technology - p. 345 15. Index - p. 365
Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy, presents the collation of chapters written by eminent scientists worldwide. CRISPR-Cas9 is a key technology for targeted genome editing and regulation in a number of organisms including mammalian cells. It is a rapid, simple, and cost-effective solution. CRISPR-Cas system has recently gained much scientific and public attention. This volume covers CRISPR-Cas9 based mammalian genome editing, creating disease models, cancer therapy, neurological, heredity, blood disorders, defective gene correction, stem cells therapy, epigenetic modifications, patents, ethics, biosafety and regulatory issues challenges and opportunities. This book is a key source of information on mammalian genome editing available in a single volume. This book will be useful for beginners in mammalian genome editing and also students, researchers, scientists, policymakers, clinicians and stakeholders interested in genome editing in several areas.
1. Chapter One: An introduction to CRISPR-Cas systems for reprogramming the genome of mammalian cells - p. 1 2. Chapter Two: CRISPR-Cas systems for genome editing of mammalian cells - p. 15 3. Chapter Three: Genome-wide detection and analysis of CRISPR-Cas off-targets - p. 31 4. Chapter Four: CRISPR-based diagnostics for detection of pathogens - p. 45 5. Chapter Five: Creating cell lines for mimicking diseases - p. 65 6. Chapter Six: Modulating Cas9 activity for precision gene editing - p. 99 7. Chapter Seven: CRISPR-Cas9 in cancer therapeutics - p. 129 8. Chapter Eight: CRISPR-Cas9 for treating hereditary diseases - p. 165 9. Chapter Nine: CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals - p. 199 10. Chapter Ten: Recent advances in stem cells and gene editing: Drug discovery and therapeutics - p. 253 11. Chapter Eleven: Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms - p. 271 12. Chapter Twelve: Genome editing in cardiovascular diseases - p. 289 13. Chapter Thirteen: CRISPR/Cas9 in epigenetics studies of health and disease - p. 326 14. Chapter Fourteen: Patents, ethics, biosafety and regulation using CRISPR technology - p. 345 15. Index - p. 365
